Novartis’ Cosentyx provides sustained resolution of psoriatic arthritis symptoms up to 2 years, data shows
October 10, 2019Research and Development Cosentyx, Novartis, pharma, psoriatic arthritis
Novartis has unveiled new findings for Cosentyx (secukinumab) which show that the therapy generated “rapid and sustained resolution” of signs …
UCB Pharma to acquire Ra Pharmaceuticals in deal valued at $2.1bn
October 10, 2019Sales and Marketing
UCB has agreed to acquire US-based Ra Pharmaceuticals for $2.1 billion in a deal that will enable the Belgian drug …
The Lung Ambition Alliance: Stronger together
October 9, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, lung cancer, pharma
Following our piece by AstraZeneca’s Patrick Connor introducing the Lung Ambition Alliance, a new cross-functional collaboration which aims to double …
FDA approves Pfenex’s osteoarthritis drug for patients at high risk of fracture
October 9, 2019Research and Development, Sales and Marketing FDA, Pfenex, osteoporosis, pharma
The FDA has awarded US approval to Pfenex’s drug PF708, it has emerged, as a treatment for osteoporosis in certain …
GSK partners with Lyell Immunopharma to develop cell therapies for cancer
October 9, 2019Research and Development
GlaxoSmithKline and Lyell Immunopharma have announced a five-year agreement to jointly develop new technologies to improve cell therapies for the …
Novartis’ ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance
October 9, 2019Research and Development Novartis, legelizumab, pharma, urticaria
Novartis has pulled back the curtain on new Phase 2b data for its IgE/FceR1 pathway-blocking drug ligelizumab, showing that the …
Johnson & Johnson ordered to pay man $8bn over breast growth
October 9, 2019Research and Development
US pharma giant Johnson & Johnson has been ordered to pay $8 billion in punitive damages to a man over …
FDA approves Clinuvel’s Scenesse for rare genetic disorder
October 9, 2019Research and Development
The US FDA has approved Clinuvel’s Scenesse (afamelanotide 16mg) as the first ever treatment for a rare genetic metabolic disorder …
Gilead’s CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma
October 8, 2019Manufacturing and Production, Sales and Marketing CAR T, CAR-T, NHS, Scotland, Scottish Medicines Consortium, pharma
News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor …
4D Pharma to collaborate with MSD in vaccine development
October 8, 2019Manufacturing and Production
4D pharma, a leader in the development of live biotherapeutics, has announced it has entered into a research collaboration to …
Multiple Sclerosis Society launches fundraising appeal to raise £100m
October 8, 2019Manufacturing and Production
The MS Society has launched a hard-hitting public appeal to raise £100m to stop multiple sclerosis. The Stop MS Appeal …
FDA approves Novartis’ Beovu injection for wet age-related macular degeneration
October 8, 2019Manufacturing and Production, Sales and Marketing Beovu, Eylea, FDA, Novartis, Regeneron, pharma
Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it …
Pfizer to develop Akcea/Ionis’ Antisense Drug for up to $1.5bn
October 8, 2019Manufacturing and Production
Pfizer and Akcea Therapeutics have entered into an exclusive worldwide licensing agreement for Akcea’s phase 2 cardiovascular and metabolic candidate …
Johnson & Johnson win FDA Breakthrough status for cancer drug Zejula
October 7, 2019Sales and Marketing
The US FDA has granted breakthrough therapy designation for Johnson & Johnson’s Zejula (niraparib) for the treatment of metastic prostate …
Gilead appoints Merdad Parsey as Chief Medical Officer
October 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Gilead Sciences have announced that Merdad Parsey will join the company as Chief Medical Officer, effective November 1st. Dr Parsey …
Breaking through limits in lung cancer: Introducing the Lung Ambition Alliance
October 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, feature, lung cancer, pharma
Lung cancer kills more patients than any other variety of cancer, accounting for around a fifth of all cancer-related deaths …
Sacklers made up to $13 billion in profits from Purdue Pharma
October 7, 2019Sales and Marketing
New court records filed in Purdue Pharma’s ongoing bankruptcy case show that the owners, the Sackler family, received $12 billion …
Scotland approves first-line NHS use of MSD’s Keytruda combo for advanced non-small cell lung cancer
October 7, 2019Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, keytruda, lung cancer, pharma
The Scottish Medicines Consortium (SMC) has announced its decision to accept MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) in combination with pemetrexed …
Pfizer reports positive phase 3 data in atopic dermatitis
October 7, 2019Sales and Marketing
Pfizer has announced top-line results from a second Phase 3 study evaluating the efficacy and safety of its oral JAK1 …
Sarepta’s investigational gene therapy shows strength in limb-girdle muscular dystrophy Type 2E
October 7, 2019Research and Development, Sales and Marketing muscular dystrophy, pharma, sarepta
Sarepta Therapeutics has revealed positive new data for its investigational gene therapy SRP-9003 in the treatment of limb-girdle muscular dystrophy …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
